NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

>>Those in the placebo arm received chambers with an inactive solution.

>>Progression-free survival (PFS) is the trial’s primary endpoint while overall survival (OS) and safety will be assessed as key secondary endpoints.
Top-line data from the trial is anticipated to be released by mid-2025.

>>Imvax also secured approximately $35m in a funding round, and half of the investment came from new investors.
To support the completion of the Phase IIb trial of IGV-001, the company secured $57m over the past 15 months.
Imvax CEO John Furey said: We are also delighted that the FDA has granted fast track designation to IGV-001.
“The last significant advancement in the standard of care for GBM – about an eight-week improvement in PFS – was nearly 20 years ago, highlighting the need for continued innovation and treatment options.

https://www.clinicaltrialsarena.com/news/imvax-glioblastoma-treatment-trial/?cf-view